Human Genome Epidemiology Literature Finder
|
Records 1 - 16 (of 16 Records) |
| Query Trace: Mesothelioma and CDKN2A[original query] |
|---|
| Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 2014 Jul 33 (28): 3748-52. Tallet A, Nault J-C, Renier A, Hysi I, Galateau-Sallé F, Cazes A, Copin M-C, Hofman P, Andujar P, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand M-C, Jean |
| Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer research 2015 Jan 75 (2): 264-9. Guo Guangwu, Chmielecki Juliann, Goparaju Chandra, Heguy Adriana, Dolgalev Igor, Carbone Michele, Seepo Sara, Meyerson Matthew, Pass Harvey |
| Molecular characterization of melanoma cases in Denmark suspected of genetic predisposition. PloS one 2015 10 (3): e0122662. Wadt Karin A W, Aoude Lauren G, Krogh Lotte, Sunde Lone, Bojesen Anders, Grønskov Karen, Wartacz Nine, Ek Jakob, Tolstrup-Andersen Morten, Klarskov-Andersen Mette, Borg Åke, Heegaard Steffen, Kiilgaard Jens F, Hansen Thomas V O, Klein Kerenaftali, Jönsson Göran, Drzewiecki Krzysztof T, Dunø Morten, Hayward Nicholas K, Gerdes Anne-Mar |
| Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing. Lung 2015 Oct . Mäki-Nevala Satu, Sarhadi Virinder Kaur, Knuuttila Aija, Scheinin Ilari, Ellonen Pekka, Lagström Sonja, Rönty Mikko, Kettunen Eeva, Husgafvel-Pursiainen Kirsti, Wolff Henrik, Knuutila Saka |
| Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma. Lung cancer (Amsterdam, Netherlands) 2016 Sep 99 155-61. Hamasaki Makoto, Matsumoto Shinji, Abe Sousei, Hamatake Daisuke, Kamei Toshiaki, Hiroshima Kenzo, Kawahara Kunimitsu, Sato Ayuko, Tsujimura Tohru, Nakatani Yukio, Yoshida Yasuhiro, Iwasaki Akinori, Nabeshima Kazu |
| CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma. Cancer letters 2016 May . Betti M, Aspesi A, Biasi A, Casalone E, Ferrante D, Ogliara P, Gironi L C, Giorgione R, Farinelli P, Grosso F, Libener R, Rosato S, Turchetti D, Maffè A, Casadio C, Ascoli V, Dianzani C, Colombo E, Piccolini E, Pavesi M, Miccoli S, Mirabelli D, Bracco C, Righi L, Boldorini R, Papotti M, Matullo G, Magnani C, Pasini B, Dianzani |
| Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Aug JCO2018785204. Panou Vasiliki, Gadiraju Meghana, Wolin Arthur, Weipert Caroline M, Skarda Emily, Husain Aliya N, Patel Jyoti D, Rose Buerkley, Zhang Shannon R, Weatherly Madison, Nelakuditi Viswateja, Knight Johnson Amy, Helgeson Maria, Fischer David, Desai Arpita, Sulai Nanna, Ritterhouse Lauren, Røe Oluf D, Turaga Kiran K, Huo Dezheng, Segal Jeremy, Kadri Sabah, Li Zejuan, Kindler Hedy L, Churpek Jane |
| BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma. Human pathology 2018 5 79 168-176. Lee Hee Eun, Molina Julian R, Sukov William R, Roden Anja C, Yi Eunhee |
| Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families. International journal of cancer 2018 11 144 (10): 2453-2464. Potjer Thomas P, Bollen Sander, Grimbergen Anneliese J E M, van Doorn Remco, Gruis Nelleke A, van Asperen Christi J, Hes Frederik J, van der Stoep Nienke, |
| Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. Cancers 2020 10 12 (10): . Pagano Maria, Ceresoli Luca Giovanni, Zucali Paolo Andrea, Pasello Giulia, Garassino Marina, Grosso Federica, Tiseo Marcello, Soto Parra Hector, Zanelli Francesca, Cappuzzo Federico, Grossi Francesco, De Marinis Filippo, Pedrazzoli Paolo, Gnoni Roberta, Bonelli Candida, Torricelli Federica, Ciarrocchi Alessia, Normanno Nicola, Pinto Carmi |
| Molecular characterization of pleomorphic mesothelioma: a multi-institutional study. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2021 9 35 (1): 82-86. Roy Somak, Galateau-Sallé Françoise, Le Stang Nolwenn, Churg Andrew, Lyons Maureen A, Attanoos Richard, Dacic San |
| Genomic landscape of pleural and peritoneal mesothelioma tumours. British journal of cancer 2022 Sep . Hiltbrunner Stefanie, Fleischmann Zoe, Sokol Ethan S, Zoche Martin, Felley-Bosco Emanuela, Curioni-Fontecedro Alessand |
| Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response. Cancers 2022 11 14 (22): . Osmanbeyoglu Hatice Ulku, Palmer Drake, Sagan April, Sementino Eleonora, Becich Michael J, Testa Joseph |
| New pathogenic germline variants identified in mesothelioma. Lung cancer (Amsterdam, Netherlands) 2023 3 179 107172. Belcaid Laila, Bertelsen Birgitte, Wadt Karin, Tuxen Ida, Spanggaard Iben, Højgaard Martin, Benn Sørensen Jens, Ravn Jesper, Lassen Ulrik, Cilius Nielsen Finn, Rohrberg Kristoffer, Westmose Yde Christi |
| Deletions of CDKN2A and MTAP Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma. Cancers 2023 10 15 (20): . Bart Vrugt, Michaela B Kirschner, Mayura Meerang, Kathrin Oehl, Ulrich Wagner, Alex Soltermann, Holger Moch, Isabelle Opitz, Peter J Wi |
| Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas. Translational lung cancer research 2024 5 13 (4): 733-748. Nancy Alnassar, Jonathan M J Derry, Giuseppe Luigi Banna, Dariusz C Gorec |
- Page last reviewed:Feb 1, 2024
- Content source: